Page 104 - 2021_04-Haematologica-web

O. di Martino et al.
Biochem Mol Biol. 2003;84(1):15-21.
9. Martino OD, Welch JS. Retinoic acid recep- tors in acute myeloid leukemia therapy.
Cancers (Basel). 2019;11(12):1915.
10. Altucci L, Gronemeyer H. The promise of retinoids to fight against cancer. Nat Rev
Cancer. 2001;1(3):181-193.
11. Arnold SL, Amory JK, Walsh TJ,
Isoherranen N. A sensitive and specific method for measurement of multiple retinoids in human serum with UHPLC- MS/MS. J Lipid Res. 2012;53(3):587-598.
12.Jones JW, Pierzchalski K, Yu J, Kane MA. Use of fast HPLC multiple reaction moni- toring cubed for endogenous retinoic acid quantification in complex matrices. Anal Chem. 2015;87(6):3222-3230.
13. Lengqvist J, Mata De Urquiza A, Bergman AC, et al. Polyunsaturated fatty acids including docosahexaenoic and arachidonic acid bind to the retinoid X receptor alpha ligand-binding domain. Mol Cell Proteomics. 2004;3(7):692-703.
14.Niu H, Fujiwara H, di Martino O, et al. Endogenous retinoid X receptor ligands in mouse hematopoietic cells. Sci Signal. 2017;10(503):eaan1011.
15. Ruhl R, Krzyzosiak A, Niewiadomska- Cimicka A, et al. 9-cis-13,14-dihy- droretinoic acid is an endogenous retinoid acting as RXR ligand in mice. PLoS Genet. 2015;11(6):e1005213.
16.Lo-Coco F, Avvisati G, Vignetti M, et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med. 2013;369(2):111-121.
17. Wang ZY, Chen Z. Acute promyelocytic leukemia: from highly fatal to highly cur- able. Blood. 2008;111(5):2505-2515.
18. Brown G, Hughes P. Retinoid differentia- tion therapy for common types of acute myeloid leukemia. Leuk Res Treatment. 2012;2012:939021.
19.Querfeld C, Rosen ST, Guitart J, et al. Comparison of selective retinoic acid receptor- and retinoic X receptor-mediated efficacy, tolerance, and survival in cuta- neous T-cell lymphoma. J Am Acad Dermatol. 2004;51(1):25-32.
20. Tsai DE, Luger SM, Andreadis C, et al. A phase I study of bexarotene, a retinoic X receptor agonist, in non-M3 acute myeloid leukemia. Clin Cancer Res. 2008;14(17):5619-5625.
21. WelchJS,NiuH,UyGL,etal.AphaseI dose escalation study of oral bexarotene in combination with intravenous decitabine in patients with AML. Am J Hematol. 2014;89(8):E103-108.
22.Niu H, Chacko J, Hadwiger G, Welch JS. Absence of natural intracellular retinoids in mouse bone marrow cells and implications for PML-RARA transformation. Blood Cancer J. 2015;5:e284.
23. Menendez-Gutierrez MP, Roszer T, Fuentes L, et al. Retinoid X receptors orchestrate osteoclast differentiation and postnatal bone remodeling. J Clin Invest. 2015;125(2):809-823.
24. Ianevski A, He L, Aittokallio T, Tang J. SynergyFinder: a web application for ana- lyzing drug combination dose-response matrix data. Bioinformatics. 2017; 33(15):2413-2415.
25. Alvarez S, Alvarez R, Khanwalkar H, et al. Retinoid receptor subtype-selective modu- lators through synthetic modifications of RARgamma agonists. Bioorg Med Chem. 2009;17(13):4345-4359.
26. Pear WS, Aster JC, Scott ML, et al. Exclusive development of T cell neoplasms in mice transplanted with bone marrow
expressing activated Notch alleles. J Exp
Med. 1996;183(5):2283-2291.
27. Carmichael CL, Metcalf D, Henley KJ, et al.
Hematopoietic overexpression of the tran- scription factor Erg induces lymphoid and erythro-megakaryocytic leukemia. Proc Natl Acad Sci U S A. 2012;109(38):15437- 15442
28. Ricote M, Snyder CS, Leung HY, Chen J, Chien KR, Glass CK. Normal hematopoiesis after conditional targeting of RXRalpha in murine hematopoietic stem/progenitor cells. J Leukoc Biol. 2006;80(4):850-861.
29. Temple KA, Cohen RN, Wondisford SR, Yu C, Deplewski D, Wondisford FE. An intact DNA-binding domain is not required for peroxisome proliferator-activated receptor gamma (PPARgamma) binding and activa- tion on some PPAR response elements. J Biol Chem. 2005;280(5):3529-3540.
30. LeoC,YangX,LiuJ,LiH,ChenJD.Roleof retinoid receptor coactivator pockets in cofactor recruitment and transcriptional regulation. J Biol Chem. 2001;276(25):23127-23134.
31. Hiromori Y, Aoki A, Nishikawa J, Nagase H, Nakanishi T. Transactivation of the human retinoid X receptor by organotins: use of site-directed mutagenesis to identify critical amino acid residues for organotin- induced transactivation. Metallomics. 2015;7(7):1180-1188.
32. Ghosh JC, Yang X, Zhang A, et al. Interactions that determine the assembly of a retinoid X receptor/corepressor complex. Proc Natl Acad Sci U S A. 2002;99(9):5842- 5847.
33. Jusu S, Presley JF, Kremer R. Phosphorylation of human retinoid X receptor alpha at Serine 260 impairs its sub- cellular localization, receptor interaction, nuclear mobility, and 1alpha,25-dihydrox- yvitamin D3-dependent DNA binding in Ras-transformed keratinocytes. J Biol Chem. 2017;292(4):1490-1509.
34. Vivat-Hannah V, Bourguet W, Gottardis M, Gronemeyer H. Separation of retinoid X receptor homo- and heterodimerization functions. Mol Cell Biol. 2003;23(21):7678- 7688.
35. Welch JS, Klco JM, Varghese N, Nagarajan R, Ley TJ. Rara haploinsufficiency modest- ly influences the phenotype of acute promyelocytic leukemia in mice. Blood. 2011;117(8):2460-2468.
36. Kastner P, Chan S. Function of RARalpha during the maturation of neutrophils. Oncogene. 2001;20(49):7178-7185.
37.Kizaki M, Dawson MI, Heyman R, et al. Effects of novel retinoid X receptor-selec- tive ligands on myeloid leukemia differen- tiation and proliferation in vitro. Blood. 1996;87(5):1977-1984.
38. Collins SJ. Retinoic acid receptors, hematopoiesis and leukemogenesis. Curr Opin Hematol. 2008;15(4):346-351.
39.Altucci L, Rossin A, Hirsch O, et al. Rexinoid-triggered differentiation and tumor-selective apoptosis of acute myeloid leukemia by protein kinase A-mediated desubordination of retinoid X receptor. Cancer Res. 2005;65(19):8754-8765.
40. Lammi J, Perlmann T, Aarnisalo P. Corepressor interaction differentiates the permissive and non-permissive retinoid X receptor heterodimers. Arch Biochem Biophys. 2008;472(2):105-114.
41. Pogenberg V, Guichou JF, Vivat-Hannah V, et al. Characterization of the interaction between retinoic acid receptor/retinoid X receptor (RAR/RXR) heterodimers and
transcriptional coactivators through struc- tural and fluorescence anisotropy studies. J Biol Chem. 2005;280(2):1625-1633.
42. Hu X, Li Y, Lazar MA. Determinants of CoRNR-dependent repression complex assembly on nuclear hormone receptors. Mol Cell Biol. 2001;21(5):1747-1758.
43. Zhang J, Hu X, Lazar MA. A novel role for helix 12 of retinoid X receptor in regulating repression. Mol Cell Biol. 1999;19(9):6448- 6457.
44. Hanish BJ, Hackney Price JF, Kaneko I, et al. A novel gene expression analytics-based approach to structure aided design of rexi- noids for development as next-generation cancer therapeutics. Steroids. 2018;135:36- 49.
45.
46.
47.
Jurutka PW, Kaneko I, Yang J, et al. Modeling, synthesis, and biological evalua- tion of potential retinoid X receptor (RXR) selective agonists: novel analogues of 4-[1- (3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro- 2-naphthyl)ethynyl]benzoic acid (bexarotene) and (E)-3-(3-(1,2,3,4-tetrahy- dro-1,1,4,4,6-pentamethylnaphthalen-7- yl)-4-hydroxypheny l)acrylic acid (CD3254). J Med Chem. 2013;56(21):8432- 8454.
Marshall PA, Jurutka PW, Wagner CE, et al. Analysis of differential secondary effects of novel rexinoids: select rexinoid X receptor ligands demonstrate differentiated side effect profiles. Pharmacol Res Perspect. 2015;3(2):e00122.
Shih AH, Jiang Y, Meydan C, et al. Mutational cooperativity linked to combi- natorial epigenetic gain of function in acute myeloid leukemia. Cancer Cell. 2015;27(4):502-515.
48. Neophytou CM, Constantinou AI. Drug delivery innovations for enhancing the anticancer potential of vitamin E isoforms and their derivatives. Biomed Res Int. 2015;2015:584862.
49. Westervelt P, Pollock JL, Oldfather KM, et al. Adaptive immunity cooperates with liposomal all-trans-retinoic acid (ATRA) to facilitate long-term molecular remissions in mice with acute promyelocytic leukemia. Proc Natl Acad Sci U S A. 2002;99(14):9468- 9473.
50. Malik SM, Collins B, Pishvaian M, Ramzi P, Marshall J, Hwang J. A phase I trial of bexarotene in combination with docetaxel in patients with advanced solid tumors. Clin Lung Cancer. 2011;12(4):231-236.
51. Noble S, Wagstaff AJ. Tretinoin. A review of its pharmacological properties and clini- cal efficacy in the topical treatment of pho- todamaged skin. Drugs Aging. 1995;6(6):479-496.
52. Tesseur I, Lo AC, Roberfroid A, et al. Comment on “ApoE-Directed Therapeutics Rapidly Clear β-Amyloid and Reverse Deficits in AD Mouse Models”. Science. 2013;340(6135):924-e.
53. Sanchez PV, Glantz ST, Scotland S, Kasner MT, Carroll M. Induced differentiation of acute myeloid leukemia cells by activation of retinoid X and liver X receptors. Leukemia. 2014;28(4):749-760.
54. McKeown MR, Corces MR, Eaton ML, et al. Super-enhancer analysis defines novel epigenomic subtypes of non-APL AML including an RARalpha dependency tar- getable by SY-1425, a potent and selective RARalpha agonist. Cancer Discov. 2017;7(10):1136-1153.
55. Mugoni V, Panella R, Cheloni G, et al. Vulnerabilities in mIDH2 AML confer sen- sitivity to APL-like targeted combination therapy. Cell Res. 2019;29(6):446-459.
1020
haematologica | 2021; 106(4)